Carregant...

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

Relapsed and refractory acute lymphoblastic leukemia (ALL) remains difficult to treat, with minimal improvement in outcomes seen in more than 2 decades despite advances in upfront therapy and improved survival for de novo ALL. Adoptive transfer of T cells engineered to express a chimeric antigen rec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Maude, Shannon L., Teachey, David T., Porter, David L., Grupp, Stephan A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2015
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4481592/
https://ncbi.nlm.nih.gov/pubmed/25999455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-12-580068
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!